Overview

The United States Pain Relief Devices Market was valued at USD 4.72 billion in 2025 and is projected to reach USD 8.05 billion by 2034, growing at a CAGR of 6.1% during the forecast period (2026-2034). The market is driven by rising chronic pain prevalence and increasing adoption of non-invasive pain management devices. The market is shifting from standard implantable neurostimulation systems toward AI-enhanced, closed-loop devices capable of automatically adjusting therapy based on real-time physiological feedback, reflecting the wider move across the US medical device industry toward personalized, adaptive pain management technology. Rising prevalence of chronic pain conditions, with the US Centers for Disease Control and Prevention estimating that roughly one in five American adults experienced chronic pain in recent years, continues to reinforce demand for effective, non-opioid pain management alternatives across the country's healthcare system. By region, the South held the largest share of the market in 2025, supported by the region's large population base and expanding pain management clinic infrastructure. The West is expected to grow at the fastest CAGR during the forecast period, aided by strong adoption of advanced neuromodulation and minimally invasive pain therapy technologies across the region's major healthcare systems.

Market Size & Share

Market Dynamics

KEY MARKET TREND:

AI-Enhanced Closed-Loop Neurostimulation and Non-Invasive Alternatives Emerging as a Transformational Trend

• Manufacturers are increasingly integrating artificial intelligence into implantable neurostimulation systems, enabling devices to continuously assess patient response and automatically adjust therapy parameters to improve pain relief efficacy over time.
• Demand for minimally invasive, non-implantable pain therapy options continues to expand, as physicians and patients seek treatment approaches that avoid the surgical risk and permanence associated with traditional implantable neurostimulation systems.
• Continued industry consolidation around peripheral nerve stimulation technology reflects growing recognition of short-term, non-permanent stimulation therapies as an important treatment option earlier in the chronic pain care continuum.
• Growing physician interest in biomechanical and gait-correction approaches to musculoskeletal pain reflects a broader diversification of device-based pain management beyond neurostimulation and ablation technology alone.

KEY MARKET DRIVER

Rising Chronic Pain Prevalence and Non-Opioid Treatment Demand is the Key Driver

• Rising prevalence of chronic pain conditions across the US adult population continues to drive demand for effective, non-opioid pain management alternatives across hospital, clinic, and home healthcare settings.
• Growing regulatory and clinical emphasis on non-addictive pain treatment alternatives, in response to the ongoing opioid crisis, continues to reinforce demand for device-based pain management technologies over traditional pharmaceutical therapy.
• Continued innovation in neuromodulation and targeted drug delivery technology, alongside favorable reimbursement policies for advanced pain therapies, continues to support sustained device adoption across the country's pain management infrastructure.
• According to the CDC, 24.3% of U.S. adults experienced chronic pain in 2023, highlighting a substantial need for effective pain-management solutions and supporting growing demand for pain relief devices, particularly non-invasive alternatives for long-term pain management.

KEY MARKET OPPORTUNITY

Peripheral Nerve Stimulation Expansion and AI-Enhanced Device Development Create Significant Market Opportunity

• Expansion of peripheral nerve stimulation therapy into earlier stages of the chronic pain care continuum offers manufacturers an opportunity to capture patients before they progress to more invasive, permanent implantable solutions.
• Growing demand for AI-enhanced, closed-loop neurostimulation systems offers established manufacturers an opportunity to differentiate premium device offerings through improved clinical outcomes and reduced need for manual therapy adjustment.
• Continued expansion of radiofrequency ablation and basivertebral nerve ablation technology into new chronic pain indications offers manufacturers an opportunity to broaden device applicability beyond traditional spinal cord stimulation use cases.
• Medtronic completed its USD 650 million acquisition of SPR Therapeutics in 2026, adding the FDA-cleared SPRINT peripheral nerve stimulation system to what the company describes as the industry's broadest pain therapy portfolio.

United States Pain Relief Devices Market Size, 2025-2034 (USD Billion)

Segmentation Analysis

Analysis by Product Type

Neurostimulation devices held the largest market share in 2025, driven by their established clinical role in the management of chronic and difficult-to-treat pain, broad applicability across conditions affecting the back, limbs, trunk, and peripheral nerves, and increasing use of spinal cord and peripheral nerve stimulation as device-based approaches for long-term pain management. Their ability to deliver targeted electrical stimulation to pain-related nerve pathways, combined with applications across neuropathic and other persistent pain conditions, continues to strengthen their position within the pain relief devices market.

Radiofrequency ablation devices are projected to grow at the fastest CAGR during the forecast period, supported by increasing preference for minimally invasive pain-management procedures that can provide durable pain relief while avoiding the greater intervention associated with conventional surgery. Their ability to target specific pain-producing nerves, improve physical function, and reduce reliance on long-term pain medication further supports their adoption among patients with chronic and persistent pain conditions.

Product Type categories include

               ·           Neurostimulation Devices (Dominating Segment)

               ·           Radiofrequency Ablation Devices (Highest CAGR Segment)

               ·           Infusion Pumps

               ·           Others

Analysis by Application

Spinal cord stimulation held the largest application share in 2025, supported by its established role in the management of refractory chronic pain and its broad clinical application across neuropathic pain, persistent pain following spinal surgery, and chronic back and leg pain. The therapy provides targeted neuromodulation by altering pain signaling within the spinal cord, making it an important device-based approach for patients whose pain remains inadequately controlled through conventional treatment options. Its established use in long-term pain management and continued application across multiple chronic pain conditions further strengthens its position within the spinal cord stimulation segment.

Intrathecal infusion pump applications are projected to grow at the fastest CAGR during the forecast period, driven by increasing interest in targeted drug-delivery approaches for severe and refractory chronic pain. These systems deliver medication directly into the intrathecal space near the spinal cord, enabling therapeutic effects with substantially lower doses than may be required through systemic administration and limiting exposure to non-target tissues. This targeted delivery approach can improve the efficiency of pain management while reducing systemic drug exposure and associated effects, supporting the growing adoption of intrathecal drug-delivery systems as an option for patients requiring long-term management of difficult-to-treat pain.

Application categories include

               ·           Spinal Cord Stimulation (Dominating Segment)

               ·           Intrathecal Infusion (Highest CAGR Segment)

               ·           Peripheral Nerve Stimulation

Analysis by End-User

Hospitals held the largest market share in 2025, supported by their central role in providing advanced pain-management procedures, particularly implantable device therapies that require specialized clinical expertise, procedural facilities, patient monitoring, and post-operative follow-up. The availability of multidisciplinary pain-management teams and the infrastructure required for procedures involving spinal cord stimulation, peripheral nerve stimulation, and other advanced pain-relief technologies further strengthens hospitals as the leading care setting for complex chronic pain management.

Home healthcare is projected to grow at the fastest CAGR during the forecast period, driven by the increasing use of portable, wearable, and non-invasive pain-management technologies that enable patients to incorporate treatment into their daily routines outside traditional clinical environments. The growing emphasis on self-management of chronic pain, combined with the development of connected and portable devices that can support pain monitoring and therapy at home, is expected to encourage greater adoption of home-based pain relief solutions and expand access to pain management beyond conventional healthcare settings.

End-User categories include

               ·           Hospitals (Dominating Segment)

               ·           Home Healthcare (Highest CAGR Segment)

Analysis by Technology

Implantable technology held the largest market share in 2025, supported by the established clinical role of spinal cord stimulation and other permanent neuromodulation systems in managing severe, refractory, and difficult-to-treat chronic pain. Their ability to provide targeted electrical stimulation to pain-related neural pathways, along with established applications across chronic back pain, limb pain, neuropathic pain, and persistent pain following spinal surgery, continues to reinforce the segment’s leading position within the pain relief devices market.

Non-invasive technology is projected to grow at the fastest CAGR during the forecast period, driven by increasing preference for accessible pain-management options that can be used without surgical implantation. The availability of technologies such as transcutaneous electrical nerve stimulation and other external stimulation-based devices enables patients to incorporate pain-management therapies into routine care with greater convenience and flexibility. Growing emphasis on non-surgical approaches for chronic pain management and the expanding availability of portable and easy-to-use devices are expected to further support adoption of non-invasive pain relief technologies.

Technology categories include

               ·           Implantable (Dominating Segment)

               ·           Non-Invasive (Highest CAGR Segment)

By Region

United States Pain Relief Devices Market Regional Analysis

United States Pain Relief Devices Market Share 2025, by Region

North America

XX%

South America

XX%

Europe

XX%

Middle East Africa

XX%

Asia Pacific

XX%

Regional Analysis

The South held the largest market share in 2025, supported by its extensive healthcare infrastructure, broad availability of specialized pain-management services, and expanding access to advanced treatment facilities across major metropolitan areas. The region’s growing network of outpatient and ambulatory surgical facilities provides an increasingly accessible setting for interventional pain-management procedures, while the presence of specialized clinicians, procedural centers, and supporting healthcare services strengthens the delivery of minimally invasive therapies. The continued expansion of outpatient care capabilities and increasing integration of pain-management services within these facilities further support the adoption of advanced pain relief devices across the region.

The West is projected to grow at the fastest CAGR during the forecast period, driven by the region’s advanced healthcare infrastructure, strong concentration of specialized pain-management services, and established clinical capabilities for delivering complex interventional therapies. The presence of specialized centers and multidisciplinary pain-management programs supports broader access to advanced neuromodulation, image-guided interventions, and minimally invasive treatment approaches for patients with chronic and refractory pain. Continued integration of innovative treatment modalities, specialized clinical expertise, and advanced procedural capabilities is expected to further strengthen the adoption of pain relief devices across the region.

Regions Covered

               ·           South (Dominating Region)

               ·           West (Fastest-Growing Region)

               ·           Midwest

               ·           Northeast

Market Share

The United States Pain Relief Devices Market is consolidated, with large diversified medical device companies including Medtronic, Boston Scientific, and Abbott holding strong positions through broad neuromodulation and pain therapy portfolios built via sustained research and development investment and strategic acquisitions, alongside specialized pain therapy companies such as Nevro and Saluda Medical competing through focused clinical innovation in spinal cord and peripheral nerve stimulation technology. Key success factors include FDA approval breadth across pain indications, clinical evidence generation, and reimbursement coverage from major payers. Leading suppliers are prioritizing continued acquisition of peripheral nerve stimulation and minimally invasive ablation technology companies, AI-enhanced closed-loop device development, and expansion of pain therapy portfolios across the full continuum of chronic pain care.

Key Players

               ·           Medtronic plc (Ireland)

               ·           Boston Scientific Corporation (US)

               ·           Abbott Laboratories (US)

               ·           Nevro Corp. (US)

               ·           Stryker Corporation (US)

               ·           Saluda Medical Pty Ltd (Australia)

               ·           Nalu Medical, Inc. (US)

               ·           Neuros Medical, Inc. (US)

               ·           Avanos Medical, Inc. (US)

               ·           AposHealth Inc. (US)

               ·           Theranica Bio-Electronics Ltd. (Israel)

               ·           NeuroMetrix, Inc. (US)

               ·           Enovis Corporation (DJO) (US)

               ·           Omron Healthcare, Inc. (Japan)

               ·           iReliev (US)

Recent Market Developments

• March 2026: Medtronic entered an exclusive agreement with Merit Medical Systems to offer the FDA-cleared ViaVerte system, expanding its U.S. pain-intervention portfolio with a minimally invasive treatment for chronic vertebrogenic lower-back pain.
• October 2025: Boston Scientific completed its acquisition of Nalu Medical, expanding its U.S. pain-relief device portfolio with the Nalu Neurostimulation System for chronic peripheral nerve pain.
• July 2025: Saluda Medical launched EVA sensing technology in the U.S. for use with the Evoke SmartLoop System, expanding its advanced spinal cord stimulation offering for chronic pain management.
• May 2025: Stryker received U.S. FDA 510(k) clearance for its OptaBlate BVN system, expanding its pain-relief device portfolio with a minimally invasive treatment for chronic vertebrogenic low-back pain.

Frequently Asked Questions

Key Questions Answered

Request a Sample

1

What is a pain relief device?

2

What is the CAGR of the United States Pain Relief Devices Market?

3

Which product type leads the United States Pain Relief Devices Market?

4

Which application dominates the market?

5

Which end-user segment is growing fastest?

6

What are the latest trends in the United States Pain Relief Devices Market?

7

Who are the leading pain relief device companies in the United States?

Why Choose IG Transformation

Speak to Analyst

Strong Industry Focus

Extensive Product Offerings

Customer Research Services

Robust Research Methodology

Comprehensive Reports

Latest Technological Developments

Value Chain Analysis

Potential Market Opportunities

Growth Dynamics

Quality Assurance

Post-sales Support

Regular Report Updates